Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7602 PK Study with Efavirenz and Food Effect
NCT06797674Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MK-7602 in malaria (7 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity up to 4 weeks, Area Under the Concentration-Time Curve from Time 0 to 24 hours and 4 more. Started Feb 2025; status: completed.
02
Drugs
MK-7602
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06797674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797674.